Continuous Infusion Of Amphotericin Research Articles

Monitored continuous infusion of amphotericin B: no renal impairment

Monitored continuous infusion of amphotericin B: no renal impairment

Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening Candida Infections

Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening <i>Candida</i> Infections

Reply: Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening Candida Infections

Reply: Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening <i>Candida</i> Infections

Successful Treatment of Pulmonary Blastomycosis with Continuously Infused Amphotericin B Deoxycholate After Failure with Liposomal Amphotericin B

To describe a case of successful treatment of severe pulmonary blastomycosis with amphotericin B deoxycholate after failure of liposomal amphotericin B. A 35-year-old male was exposed to damp decomposing wood while cleaning his basement. He subsequently developed a cough, malaise, fever, nausea, vomiting, and diarrhea. He was admitted to the hospital and intubated for worsening pulmonary symptoms. Microscopic examination of his sputum indicated Blastomyces dermatitidis. Liposomal amphotericin B was administered for 6 days, but the patient's temperature reached 39.6 °C and his white blood cell (WBC) count reached 52,300/μL. Extensive consolidation of both lungs fields was observed on chest X-ray. Because of progressive clinical deterioration, the treatment was switched to amphotericin B deoxycholate by continuous infusion. That change resulted in clinical improvement, with abrupt reductions (within 48 hours) in temperature and the WBC count. By day 14 of therapy (day 8 of amphotericin B deoxycholate), the chest X-ray showed improvement in diffuse airspace filling. After 16 days of amphotericin B treatment, intravenous followed by oral voriconazole was administered for 3 months. Eight months later the patient's strength had improved significantly, but he still had occasional episodes of shortness of breath. The management of blastomycosis is challenging because of the lack of clinically supporting data. The gold standard for severe pulmonary blastomycosis had been amphotericin B deoxycholate; however, improved safety data with liposomal amphotericin B for other fungal infections has suggested this as an effective alternative. This report describes a patient with severe pulmonary blastomycosis failing 6 days of liposomal amphotericin B, yet he tolerated and clinically responded to continuous infusion of amphotericin B deoxycholate. Based on this case report and a simulated pharmacokinetic/pharmaco dynamic analysis, continuous infusion of amphotericin B deoxycholate may be a reasonable option for enhanced efficacy and minimal toxicity in patients with blastomycosis. Ours is the first case report to use continuous infusion of amphotericin B deoxycholate for the management of pulmonary blastomycosis. These results suggest that liposomal amphotericin B may not be adequate in some patients for the management of B. dermatitidis pulmonary infections.

Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment

The combination of amphotericin B and sodium deoxycholate is the formulation most used in clinical practice. The development of new agents such as amphotericin with lipid formulations, caspofungin, voriconazole and other azolic derivatives, promoted alternatives to amphotericin B deoxycholate. However, because of the high cost of these new drugs, their use is difficult in a scenario of limited resources. A few strategies have been devised to make the use of amphotericin B deoxycholate less toxic. In this review, we seek to describe the accumulated knowledge about this molecule, with focus on its use in continuous infusion, which appears to be an alternative to reduce toxicity, while maintaining its clinical efficacy.

Continuous Infusion of Amphotericin B deoxycholate in the Treatment of Cryptococcal Meningoencephalitis: Analysis of Safety and Fungicidal Activity

Continuous Infusion of Amphotericin B deoxycholate in the Treatment of Cryptococcal Meningoencephalitis: Analysis of Safety and Fungicidal Activity

Twenty‐four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients

Internal Medicine JournalVolume 35, Issue 6 p. 374-374 Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients P. Hall, P. Hall Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 1 G. Kennedy, G. Kennedy Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 J. Morton, J. Morton Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 G. R. Hill, G. R. Hill Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 S. Durrant, S. Durrant Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 P. Hall, P. Hall Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 1 G. Kennedy, G. Kennedy Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 J. Morton, J. Morton Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 G. R. Hill, G. R. Hill Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 S. Durrant, S. Durrant Departments of 1Pharmacyand 2Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland,AustraliaSearch for more papers by this author 2 First published: 13 May 2005 https://doi.org/10.1111/j.1445-5994.2005.00847.xCitations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume35, Issue6June 2005Pages 374-374 RelatedInformation